Treg-targeted efficient-inducible platform for collagen-induced arthritis treatment
Source abstract
Abstract
Regulatory T cells (Tregs) display great promise in rheumatoid arthritis (RA) therapy. However, their low number and differentiation rate limit their further application in the clinics. In the present study, we first optimized a combination of IL-2, TGF-β and cyclin dependent kinase inhibitor AS2863619 (IL-2/TGF-β/AS), which could induce Tregs with high efficiency in vitro. After the induced Tregs (iTregs) were confirmed to suppress lymphocyte proliferation and pro-inflammatory T help cells (Th1 and Th17) activation, a chitosan-stabilized nanoparticle drug delivery system (NDDS) was developed according to the optimized formula of IL-2/TGF-β/AS. In vivo study, the NDDS was injected into the knees of mice with collagen-induced arthritis (CIA). As a result, the NDDS remarkably reduced the pathological score of the CIA, alleviated the inflammatory cell infiltration and synovial hyperplasia, and minimized cartilage tissue damage in the knee joint of the CIA mice. Mechanically, the NDDS administration promoted Treg differentiation and decreased Th17 production, consequently reversing the ratio of Treg/Th17, and reducing the secretion of TNF-α in the sera, which facilitated to relieve the severity and progression of arthritis. In sum, NDDS capable of efficiently inducing Tregs were constructed successfully and provided a potential platform for treating RA by restoring the equilibrium of Treg/Th17 destroyed in RA.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · T-cell and B-cell Immunology · Chemokine receptors and signaling
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Rheumatoid arthritis10.7326/AITC201901010 ↗
2. Immune-bone interplay in the structural damage in rheumatoid arthritis10.1111/cei.13188 ↗
3. Effector functions of CD4+ T cells at the site of local autoimmune inflammation-lessons from rheumatoid arthritis10.3389/fimmu.2019.00353 ↗
4. Review: transcriptional regulation of CD4+ T cell differentiation in experimentally induced arthritis and rheumatoid arthritis10.1002/art.40398 ↗
5. Differences in safety of nonsteroidal antiinflammatory drugs in patients with osteoarthritis and patients with rheumatoid arthritis: a randomized clinical trial10.1002/art.40400 ↗
6. Strategies toward rheumatoid arthritis therapy; the old and the new10.1002/jcp.27860 ↗
7. Defining refractory rheumatoid arthritis10.1136/annrheumdis-2017-212862 ↗
8. Synthesis and biological activities of chemical drugs for the treatment of rheumatoid arthritis10.1007/s41061-019-0252-5 ↗
9. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies10.12688/f1000research.18688.1 ↗
10. Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases10.1038/s41422-020-0324-7 ↗
11. The role of Treg cell subsets in allergic disease
12. Induced, but not natural, regulatory T cells retain phenotype and function following exposure to inflamed synovial fibroblasts10.1126/sciadv.abb0606 ↗
13. Treg cells in health and autoimmune diseases: new insights from single cell analysis10.1016/j.jaut.2019.102376 ↗
14. Ectopic FOXP3 expression in combination with TGF-β1 and IL-2 stimulation generates limited suppressive function in human primary activated thymocytes ex vivo10.3390/biomedicines9050461 ↗
15. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T(reg) cells by inhibition of CDK8/1910.1126/sciimmunol.aaw2707 ↗
16. The evolution of commercial drug delivery technologies10.1038/s41551-021-00698-w ↗
17. Controlled release drug delivery systems10.1080/10837450.2018.1534376 ↗
18. Review on nanoparticles and nanostructured materials: bioimaging, biosensing, drug delivery, tissue engineering, antimicrobial, and agro-food applications10.3390/nano12030457 ↗
19. Recent advancements in serum albumin-based nanovehicles toward potential cancer diagnosis and therapy10.3389/fchem.2021.746646 ↗
20. Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: a critical review10.1016/j.ijbiomac.2021.10.040 ↗
21. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer10.1093/annonc/mdl104 ↗
22. Photosensitizer-induced HPV16 E7 nanovaccines for cervical cancer immunotherapy10.1016/j.biomaterials.2022.121411 ↗
23. Piezo1-targeted aerosol inhalation nanoparticles for acute lung injury10.1016/j.jmst.2022.08.043 ↗
24. Stability of housekeeping genes in inflamed joints of spontaneous and collagen-induced arthritis in DBA/1 mice10.1007/s00011-021-01453-2 ↗
25. Therapeutic effect of quercetin in collagen-induced arthritis10.1016/j.biopha.2017.03.026 ↗
26. Honeycomb-like hydrogel microspheres for 3D bulk construction of tumor models10.34133/2022/9809763 ↗
27. [Boosting Treg activity by TNFR2 and GITR agonists: new therapeutic approaches for autoimmune diseases]
28. What did we learn from CTLA-4 insufficiency on the human immune system?10.1111/imr.12721 ↗
29. Transcription factor IRF4 dysfunction affects the immunosuppressive function of Treg cells in patients with primary immune thrombocytopenia10.1155/2019/1050285 ↗
30. Immunotherapy with iTreg and nTreg cells in a murine model of inflammatory bowel disease10.1007/978-1-4939-3603-8_19 ↗
31. Th17 cells in autoimmune and infectious diseases
32. Controlled dual delivery of BMP-2 and dexamethasone by nanoparticle-embedded electrospun nanofibers for the efficient repair of critical-sized rat calvarial defect10.1016/j.biomaterials.2014.10.015 ↗
33. C57BL/6 mice need MHC class II Aq to develop collagen-induced arthritis dependent on autoreactive T cells10.1136/annrheumdis-2012-202055 ↗
34. Immunometabolism in the development of rheumatoid arthritis10.1111/imr.12838 ↗
35. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents10.1016/j.autrev.2019.102398 ↗
36. Regulation of Th1/Th2 and Th17/Treg by pDC/mDC imbalance in primary immune thrombocytopenia10.1177/15353702211009787 ↗
37. Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis10.1016/j.jneuroim.2021.577583 ↗
38. An overview of drug delivery systems10.1007/978-1-4939-9798-5_1 ↗
39. Microemulsion and bovine serum albumin nanoparticles as a novel hybrid nanocarrier system for efficient multifunctional drug delivery10.1002/jbm.a.36935 ↗
40. Biodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice10.1039/D1BM01637G ↗
41. Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy10.1007/s12272-020-01204-7 ↗
42. Albumin nanostructures as advanced drug delivery systems10.1080/17425247.2016.1193149 ↗
43. Protein-based nanoparticles as drug delivery systems10.3390/pharmaceutics12070604 ↗
44. Piezo1-targeted aerosol inhalation nanoparticles for acute lung injury